Cibus
Cibus' revenue fell 14.6% to $4 million in fiscal 2025. Its operating margin was −2,680.1%, up from −6,062.8% a year earlier. Free cash flow was −$51 million. The diluted share count rose 97.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cibus does
Cibus is an agricultural biotechnology company. It uses gene editing, a way of making precise changes to a plant's DNA, to develop plant traits: built-in characteristics such as tolerance to weed killers or resistance to disease. Its process, which it calls the Rapid Trait Development System, is meant to let seed companies add these traits to their own best seed lines faster than traditional plant breeding.
Cibus plans to make money by licensing its traits to seed companies in exchange for royalties on the seed they sell. Its main program is rice that tolerates weed killers, aimed first at Latin America and the United States. It also works on ingredients such as lauric oils and fragrances made with yeast and fermentation, partly paid for by partners. It names large agricultural chemical companies, including BASF, Bayer Crop Science, Corteva and Syngenta, as its most likely competitors, along with smaller gene-editing firms; some competitors may also be customers.
Cibus has narrowed its work to save money. In 2025 it cut about 34 full-time jobs, and it cut another 15 in March 2026 while moving its core work to San Diego. At the end of 2025 it had 118 full-time employees. Cibus says there is substantial doubt about its ability to keep operating without raising more money soon.
Its biggest risks, as it describes them
- Running out of money: it has lost money for years and needs new financing soon to keep operating.
- Seed companies may not license its traits, or may not turn them into products farmers buy.
- Its research and field trials may be slower than planned or may not work.
- Rules for gene-edited crops differ by country and are still changing, and adverse changes could block its products.
- Competition from large agricultural chemical companies with far more money and staff, and disputes over patents.
Income statement
Cibus lost money in fiscal 2025: a net loss of $127 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 14 | 4 | 33 | 14 | 10 |
| Debt incl. finance leases | 18 | 0 | 2 | 1 | 0 |
| Net debt (negative means net cash) | 3 | −3 | −31 | −14 | −9 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.3x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −20.5x | −298.3x | −2,592.5x | −2,246.9x | −1,234.5x |
| Current ratio | 3.1x | 2.5x | 1.6x | 0.8x | 0.7x |
| Quick ratio | 3.1x | 2.5x | 1.6x | 0.8x | 0.7x |
Cash flow
Projections
Project Cibus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Cibus says to expect
- Exit of 2026: annualized net cash usage run rate
Continue to anticipate exiting 2026 at an annual net cash usage run-rate of approximately $35 million.
Insider trades
No officer, director or 10% owner of Cibus reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 3 of 8 | 3 of 8 |
| Rule of 40 | −1,723.7% | −1,246.3% | −1,420.8% |
| Altman Z'' | −5.15 | −11.44 | −11.34 |
| Accruals ratio | −78.1% | −43.2% | −23.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 2 of 8 | 3 of 8 | 3 of 8 |
Compare
Put Cibus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cibus | FY25 | −14.6% | −2,680.1% | −1,406.1% | −169.5% | — | 3 | |
| SenesTech | FY25 | 19.6% | −292.9% | −265.1% | −389.3% | — | 5 | Compare |
| Intrepid Potash | FY25 | 17.1% | 3.6% | 8.6% | — | — | — | Compare |
| American Vanguard | FY25 | −5.9% | −5.5% | −4.9% | −6.2% | — | 5 | Compare |
| LSB Industries | FY25 | 17.8% | 9.3% | 2.9% | 5.3% | 2.2x | 8 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 7 | 24 | 26 | 0 | 2 | 4 | 4 |
| Revenue growth | −68.6% | 27.3% | −53.5% | 2,991.5% | 226.9% | 9.0% | −99.4% | 1,057.3% | 134.6% | −14.6% |
| Gross profit | 0 | 0 | 0 | −2 | −11 | −3 | 0 | — | — | — |
| Research and development | 6 | 12 | 10 | 12 | 11 | 11 | 12 | 42 | 50 | 44 |
| Operating income | −12 | −26 | −28 | −40 | −44 | −29 | −22 | −319 | −258 | −98 |
| Net income | −12 | −26 | −28 | −40 | −45 | −29 | −17 | −268 | −251 | −127 |
| Diluted EPS (US$) | −31.00 | −56.00 | −45.50 | −60.50 | −66.00 | −39.00 | −18.36 | −25.95 | −10.83 | −2.78 |
| Diluted shares (millions) | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 10 | 23 | 46 |
| Cash flow | ||||||||||
| Cash from operations | −9 | −13 | −20 | −32 | −44 | −19 | −19 | −46 | −58 | −51 |
| Capital expenditure | 10 | 1 | 2 | 3 | 2 | 0 | 2 | 4 | 1 | 1 |
| Free cash flow | −20 | −14 | −22 | −35 | −45 | −19 | −21 | −51 | −59 | −51 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 12 | 4 | 9 | 5 | 2 | 4 | 16 | 11 | 8 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 5 | 57 | 95 | 60 | 30 | 14 | 4 | 33 | 14 | 10 |
| Debt incl. finance leases | — | — | — | — | 20 | 18 | 0 | 2 | 1 | 0 |
| Total assets | 17 | 72 | 119 | 88 | 63 | 37 | 22 | 544 | 350 | 305 |
| Total liabilities | 4 | 15 | 25 | 26 | 26 | 23 | 15 | 206 | 252 | 283 |
| Shareholders' equity | 13 | 58 | 93 | 62 | 37 | 14 | 7 | 294 | 92 | 22 |
| Margins and ratios | ||||||||||
| Gross margin | 49.9% | 100.0% | 100.0% | −27.2% | −47.3% | −9.9% | 100.0% | — | — | — |
| Operating margin | −3,034.8% | −5,076.6% | −11,913.1% | −543.8% | −183.8% | −112.9% | −14,248.4% | −17,550.0% | −6,062.8% | −2,680.1% |
| Net margin | −3,029.1% | −5,114.2% | −11,820.8% | −542.9% | −188.0% | −112.4% | −10,758.6% | −14,729.1% | −5,898.4% | −3,492.3% |
| Free cash flow margin | −4,927.6% | −2,670.1% | −9,342.8% | −478.6% | −190.6% | −74.3% | −13,301.9% | −2,781.0% | −1,380.8% | −1,406.1% |
| Rule of 40 (growth + FCF margin) | −4,996.2% | −2,642.8% | −9,396.3% | 2,512.9% | 36.3% | −65.3% | −13,401.3% | −1,723.7% | −1,246.3% | −1,420.8% |
| Return on capital | — | — | — | — | — | −104.8% | −165.2% | −189.2% | −119.8% | −169.5% |
| Return on equity | — | −73.6% | −37.0% | −50.8% | −90.2% | −114.5% | −158.1% | −178.0% | −130.4% | −223.0% |
| Return on assets | — | −58.5% | −29.2% | −38.3% | −59.2% | −58.1% | −56.7% | −94.4% | −56.2% | −38.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |